Aktis Oncology, Inc. Common stock Total Assets
Aktis Oncology, Inc. Common stock total assets. Based on the latest financial reports, Aktis Oncology, Inc. Common stock (AKTS) holds total assets worth $279.04 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AKTS market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Aktis Oncology, Inc. Common stock (2013–2024)
Total assets of Aktis Oncology, Inc. Common stock from 2013 to 2024. This chart illustrates how Aktis Oncology, Inc. Common stock's total assets have evolved over time, based on quarterly financial data. See AKTS stock price and chart for real-time trading data and today's change.
Aktis Oncology, Inc. Common stock - Asset Composition Analysis
Aktis Oncology, Inc. Common stock Total Assets Breakdown (December 2024)
Aktis Oncology, Inc. Common stock total assets breakdown as of December 2024. Aktis Oncology, Inc. Common stock's total assets of $279.04 Million consist of 92.2% current assets and 7.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.4% |
| Accounts Receivable | $5.29 Million | 1.6% |
| Inventory | $2.22 Million | 0.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $12.56 Million | 3.9% |
| Goodwill | $6.51 Million | 2.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Aktis Oncology, Inc. Common stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Aktis Oncology, Inc. Common stock working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aktis Oncology, Inc. Common stock's current assets represent 92.2% of total assets in 2024, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2024, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 3.9% of total assets.
Aktis Oncology, Inc. Common stock Competitors by Total Assets
Key competitors of Aktis Oncology, Inc. Common stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Aktis Oncology, Inc. Common stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.27 | 18.55 | 9.40 |
| Quick Ratio | 9.27 | 18.36 | 9.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $222.51 Million | $298.41 Million | $35.10 Million |
Aktis Oncology, Inc. Common stock - Advanced Valuation Insights
This section examines the relationship between Aktis Oncology, Inc. Common stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 2.36 |
| Asset Growth Rate (YoY) | 367.7% |
| Total Assets | $326.18 Million |
| Market Capitalization | $769.87 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Aktis Oncology, Inc. Common stock's assets at a significant premium (2.36x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Aktis Oncology, Inc. Common stock's assets grew by 367.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aktis Oncology, Inc. Common stock (2013–2024)
The table below shows the annual total assets of Aktis Oncology, Inc. Common stock from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $326.18 Million | +367.70% |
| 2024-06-30 | $69.74 Million | -43.00% |
| 2023-12-31 | $122.36 Million | -17.84% |
| 2023-06-30 | $148.92 Million | +7.66% |
| 2022-12-31 | $138.32 Million | -14.27% |
| 2022-06-30 | $161.34 Million | 0.00% |
| 2021-12-31 | $161.34 Million | +29.08% |
| 2021-06-30 | $124.99 Million | +74.98% |
| 2020-12-31 | $71.43 Million | 0.00% |
| 2020-06-30 | $71.43 Million | +48.98% |
| 2019-12-31 | $47.95 Million | 0.00% |
| 2019-06-30 | $47.95 Million | +63.60% |
| 2018-12-31 | $29.31 Million | 0.00% |
| 2018-06-30 | $29.31 Million | +61.99% |
| 2017-12-31 | $18.09 Million | 0.00% |
| 2017-06-30 | $18.09 Million | +298.27% |
| 2016-06-30 | $4.54 Million | 0.00% |
| 2015-12-31 | $4.54 Million | +0.66% |
| 2015-06-30 | $4.51 Million | 0.00% |
| 2014-12-31 | $4.51 Million | +47297.76% |
| 2014-06-30 | $9.52K | +4.63% |
| 2013-12-31 | $9.10K | 0.00% |
| 2013-06-30 | $9.10K | -- |
About Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatmen… Read more